EZH2-Associated Hypermethylated Gene Signature Predicts Immunotherapy Response and Implicates DUSP5 in Tumor-Immune Regulation in Triple-Negative Breast Cancer

Mingzhan Xue, Sujitha Jeya, Reem Elasad, Sarra Mestiri, Fares Al Ejeh, Mariam Al-Muftah · 2026

Read EZH2-Associated Hypermethylated Gene Signature Predicts Immunotherapy Response and Implicates DUSP5 in Tumor-Immune Regulation in Triple-Negative Breast Cancer by Mingzhan Xue, Sujitha Jeya, Reem Elasad, Sarra Mestiri, Fares Al Ejeh, Mariam Al-Muftah (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13204126.txt.

Description

Mingzhan Xue and co-authors hunt a gene mark in a 2026 study of the harshest breast cancer kind. That kind lacks the three marks that guide most care, so shield drugs are a hope with few guides. A gene-silencer in the tumor may shut the genes that would let shields in.

The team sifted data for genes the silencer keeps shut and built a mark from their tags. The mark sorts who may gain from shield care. One shut gene, a brake on a swell path, stands out as a live actor in the tumor shield play. Doctors gain a mark with a tale, not just a score.

Catalog record

CREATORMingzhan Xue, Sujitha Jeya, Reem Elasad, Sarra Mestiri, Fares Al Ejeh, Mariam Al-Muftah
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE43 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13204126

Browse the full library · About the Tower of Babel